

Riverstone's 4QFY25 net profit rises 3.7% q-o-q to RM54.0 million on resilient cleanroom demand from AI infrastructure despite FX impact

- Revenue for 4QFY25 increased by 1.3% q-o-q to RM250.7 million, supported by growing cleanroom demand from AI infrastructure and modest sales growth in the healthcare segment.
- Gross profit moderated by 3.0% q-o-q to RM74.2 million in 4QFY25, with gross margin narrowing 1.3 ppts to 29.6%, primarily due to foreign exchange impact arising from the strengthening of Malaysia ringgit against US dollar.
- Proposes a final dividend of 5.0 sen (RM) per ordinary share and a special dividend of 4.0 sen (RM) per ordinary share. Total FY25 dividend reaches 17.0 sen (RM), translating to a 121.3% payout and a 6.9%¹ yield.
- Remains strategically focused on the cleanroom and customised healthcare glove segments, which show sustained momentum, while staying selective in the generic healthcare segment amid a more competitive environment.

Financial Highlights (RM' million)	FY25	FY24	y-o-y (%)	4Q25	3Q25	4Q24	q-o-q (%)	y-o-y (%)
Revenue	995.3	1,072.8	(7.2)	250.7	247.5	278.0	1.3	(9.8)
Gross Profit	298.7	390.1	(23.4)	74.2	76.6	89.8	(3.0)	(17.3)
Gross Profit Margin	30.0%	36.4%	(6.4 ppts)	29.6%	30.9%	32.3%	(1.3 ppts)	(2.7 ppts)
Profit Before Tax	264.5	358.7	(26.3)	66.1	67.2	84.6	(1.6)	(21.8)
Net Profit	207.8	286.9	(27.6)	54.0	52.0	70.0	3.7	(23.0)
Diluted EPS (sen)	14.02	19.36	(27.6)	3.64	3.51	4.73	3.7	(23.0)

pts = percentage points

Singapore, 25 February 2026 – SGX Mainboard-listed Riverstone Holdings Limited ("**Riverstone**" or together with its subsidiaries, the "**Group**") [立合斯顿有限公司], a leading manufacturer of specialised cleanroom and healthcare gloves, has announced its financial results for the fourth quarter ("**4QFY25**") and twelve months ("**FY25**") ended 31 December 2025.

Revenue for 4QFY25 improved 1.3% quarter-on-quarter ("**q-o-q**") to RM250.7 million, supported by growing cleanroom demand amid continued expansion in data centre and AI-related industries as well as a modest sales volume increase in healthcare. Despite encouraging sales volume growth, revenue was impacted by lower average selling prices ("**ASP**") of generic healthcare gloves due to intensified competition as well as foreign exchange translation losses arising from the rapid strengthening of the Malaysian ringgit against the US dollar. As such, 4QFY25 revenue declined 9.8% y-o-y and FY25 revenue fell 7.2% y-o-y.

Gross profit for 4QFY25 moderated by 3.0% q-o-q to RM74.2 million, with gross profit margin easing by 1.3 percentage points ("**ppts**") to 29.6%, largely due to the foreign exchange losses.

¹ Calculated based on a share price of S\$0.795 and an MYR/SGD exchange rate of 3.0770, as of 23 February 2026.

Accordingly, the Group's 4QFY25 net profit closed at RM54.0 million, up 3.7% q-o-q but down 23.0% y-o-y. Notably, net profit has increased for three consecutive quarters, as solid growth in the cleanroom and customised healthcare segments, together with prudent cost management that continues to underpin earnings resilience.

The Group remains committed to delivering value to shareholders. The Board of Directors is pleased to recommend a final dividend of 5.0 sen (RM) per ordinary share, subject to shareholders' approval in the forthcoming Annual General Meeting, as well as a special interim dividend of 4.0 sen (RM) per ordinary share. Including the 8.0 sen (RM) dividend distributed in the past three quarters, the cumulative dividend for FY25 reaches 17.00 sen (RM) per ordinary share, translating to a dividend payout ratio of 121.3% and a dividend yield of 6.9%¹.

Executive Chairman and CEO, **Mr. Wong Teek Son** commented, *"2025 was a challenging year for glove manufacturers as competition in the generic segment intensified amid aggressive market share competition while foreign exchange headwinds weighed on our reported performance. Encouragingly, our core cleanroom segment continued to produce solid results supported by AI-driven demand, particularly from the memory and storage sectors. We believe this momentum is likely to extend into 2026, with gradual volume growth expected as end-users including AI hyperscalers continue to raise CAPEX.*

That said, we entered 2026 amid ongoing foreign exchange fluctuations and a temporary hike in raw material costs, which are expected to affect our near-term reported performance. As the Group continues to shift its focus away from low-margin generic volumes towards its core cleanroom and customised healthcare segments, and with raw material costs expected to normalise from 2QFY26, we remain confident in the long-term resilience of our business."

END

About Riverstone Holdings Limited (“Riverstone” or 立合斯顿有限公司)

Malaysia-based Riverstone is a global market leader in the manufacturing of nitrile and natural rubber clean room gloves used in highly controlled and critical environments as well as premium nitrile gloves used in the healthcare industry. The company's proprietary “RS Riverstone Resources” brand is the preferred cleanroom glove for use in high-tech manufacturing industries. The company also manufactures cleanroom consumables such as finger cots and facemasks. Its customers are global leaders in the HDD, LCD, semiconductor, consumer electronics, pharmaceutical and healthcare industries. The company employs approximately 3,000 people throughout its six manufacturing facilities in Malaysia (4), Thailand (1) and China (1) with an annual production capacity of 10.5 billion gloves. It also has an established global network of sales offices to serve its customers in Singapore, Malaysia, Thailand, the Philippines, China and the U.S. Riverstone was listed on the Mainboard of the Singapore Exchange in 2006. (www.riverstone.com.my)

Issued for and on behalf of Riverstone Holdings Limited by Financial PR

Investor Relations:

Kamal SAMUEL / Vicki ZHOU / Vern Theng LIM
Email: riverstone@financialpr.com.sg
Phone: +65 6438 2990